Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-κB pathway

European Journal of Pharmacology

Volumn 588, Issue 1, 2008, Pages 124-133

  Tsai, Huei Yann ^a   Lin, Hui Yi ^a   Fong, Yi Chin ^c   Wu, Jin Bin ^a   Chen, Yuh Fung ^a   Tsuzuki, Minoru ^a,b   Tang, Chih Hsin ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ERK; NF B; Osteoclast; p38; Paeonol

Indexed keywords

ALENDRONIC ACID; COLONY STIMULATING FACTOR 1; ESTRADIOL; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PEONOL; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE ATROPHY; BONE MARROW CELL; CELL ACTIVITY; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL LINE; CELL MATURATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FETUS; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RABBIT; RAT; SPRAGUE DAWLEY RAT; STROMA CELL;

ACETOPHENONES; ALKALINE PHOSPHATASE; ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENES, REPORTER; MICE; MICE, INBRED ICR; NF-KAPPA B; OSTEOCALCIN; OSTEOCLASTS; OSTEOGENESIS; OSTEOPONTIN; OVARIECTOMY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 44249098462     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.04.024     Document Type: Article

References (29)

1. Berg C., Neumeyer K., and Kirkpatrick P. Teriparatide. Nat. Rev. Drug Discov. 2 (2003) 257-258
2. Bossard M.J., Tomaszek T.A., Levy M.A., Ijames C.F., Huddleston M.J., Briand J., Thompson S., Halpert S., Veber D.F., Carr S.A., Meek T.D., and Tew D.G. Mechanism of inhibition of cathepsin K by potent, selective 1, 5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteases. Biochemistry 38 (1999) 15893-15902
3. Chou T.C. Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia. Br. J. Pharmacol. 139 (2003) 1146-1152
4. Chung J.G. Paeonol promotion of DNA adduct formation and arylamines N-acetyltransferase activity in human colon tumour cells. Food Chem. Toxicol. 37 (1999) 327-334
5. Cobb M.H., and Goldsmith E.J. How MAP kinases are regulated. J. Biol. Chem. 270 (1995) 14843-14846
6. Darnay B.G., Haridas V., Ni J., Moore P.A., and Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-kB (RANK): interaction with tumor necrosis factor receptor-associated factors and activation of NF-kB and c-Jun N-terminal kinase. J. Biol. Chem. 273 (1998) 20551-20555
7. Darnay B.G., Ni J., Moore P.A., and Aggarwal B.B. Activation of NF-kB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kB-inducing kinase: identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274 (1999) 7724-7731
8. Ducy P., Schinke T., and Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 289 (2000) 1501-1504
9. Goltzman D. Discoveries, drugs and skeletal disorders. Nat. Rev. Drug Discov. 1 (2002) 784-796
10. Hirai A., Terano T., Hamazaki T., Sajiki J., Saito H., Tahara K., Tamura Y., and Kumagai A. Studies on the mechanism of antiaggregatory effect of Moutan Cortex. Thromb. Res. 31 (1983) 29-40
11. Ishiguro K., Ando T., Maeda O., Hasegawa M., Kadomatsu K., Ohmiya N., Niwa Y., Xavier R., and Goto H. Paeonol attenuates TNBS-induced colitis by inhibiting NF-kappaB and STAT1 transactivation. Toxicol. Appl. Pharmacol. 217 (2006) 35-42
12. Julian M., Quinn M., Elliott J., Gillespie M.T., and Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139 (1998) 4424-4427
13. Lee S.Y., Reichlin A., Santana A., Sokol K.A., Nussenzweig M.C., and Choi Y. TRAF2 is essential for JNK but not NF-kB activation and regulates lymphocyte proliferation and survival. Immunity 7 (1997) 703-713
14. Mi X.J., Chen S.W., Wang W.J., Wang R., Zhang Y.J., Li W.J., and Li Y.L. Anxiolytic-like effect of paeonol in mice. Pharmacol. Biochem. Behav. 81 (2005) 683-687
15. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., Pando M.P., Asano T., Verma I.M., Oda H., Nakamura K., and Tanaka S. Reciprocal role of ERK and NF-kB pathways in survival and activation of osteoclasts. J. Cell Biol. 148 (2000) 333-342
16. Nishida E., and Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 18 (1993) 128-131
17. Nizamutdinova I.T., Oh H.M., Min Y.N., Park S.H., Lee M.J., Kim J.S., Yean M.H., Kang S.S., Kim Y.S., Chang K.C., and Kim H.J. Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways. Int. Immunopharmacol. 7 (2007) 343-350
18. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 (2002) 1508-1514
19. Tang C.H., Yang R.S., and Fu W.M. Prostaglandin E2 stimulates fibronectin expression through EP1 receptor, phospholipase C, protein kinase Calpha, and c-Src pathway in primary cultured rat osteoblasts. J. Biol. Chem. 280 (2005) 22907-22916
20. Tang C.H., Yang R.S., Huang T.H., Lu D.Y., Chuang W.J., Huang T.F., and Fu W.M. Ultrasound stimulates cyclooxygenase-2 expression and increases bone formation through integrin, focal adhesion kinase, phosphatidylinositol 3-kinase, and Akt pathway in osteoblasts. Mol. Pharmacol. 69 (2006) 2047-2057
21. Tang C.H., Hsu T.L., Lin W.W., Lai M.Z., Yang R.S., Hsieh S.L., and Fu W.M. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J. Biol. Chem. 282 (2007) 2346-2354
22. Tang C.H., Yang R.S., Chen Y.F., and Fu W.M. Basic fibroblast growth factor stimulates fibronectin expression through phospholipase C gamma, protein kinase C alpha, c-Src, NF-kappaB, and p300 pathway in osteoblasts. J. Cell. Physiol. 211 (2007) 45-55
23. Teitelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1505
24. Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., Koga T., Martin T.J., and Suda T. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 7260-7264
25. van't Hof R.J., and Ralston S.H. Nitric oxide and bone. Immunology 103 (2001) 255-261
26. Xu S.P., Sun G.P., Shen Y.X., Wei W., Peng W.R., and Wang H. Antiproliferation and apoptosis induction of paeonol in HepG2 cells. World J. Gastroenterol. 13 (2007) 250-256
27. Yang R.S., Lin W.L., Chen Y.Z., Tang C.H., Huang T.H., Lu B.Y., and Fu W.M. Regulation by ultrasound treatment on the integrin expression and differentiation of osteoblasts. Bone 36 (2005) 276-283
28. Yao G.Q., Sun B., Hammond E.E., Spencer E.N., Horowitz M.C., Insogna K.L., and Weir E.C. The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells. J. Biol. Chem. 273 (1998) 4119-4128
29. Yasuda H., Shima N., and Nakagawa N. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3597-3602